Athersys Stock

Athersys Operating Expenses

Delisted

The Total Operating Expenses of Athersys (ATHX) as of Aug 23, 2026 is 40.83 M USD. In the previous year, Total Operating Expenses was 80.91 M USD — a change of -49.54% (lower).

Operating Expenses

40.83 MUSD

YoY

-49.54%

Last updated:

Total Operating Expenses of Athersys is 2026 40.83 M USD. Total Operating Expenses of Athersys was 2025 80.91 M USD. It decreases by -49.54% lower compared to the previous year.

The Athersys Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2016
32.67 M USD
Jan 1, 2017
36.31 M USD
Jan 1, 2018
49.10 M USD
Jan 1, 2019
50.42 M USD
Jan 1, 2020
78.88 M USD
Jan 1, 2021
91.15 M USD
Jan 1, 2022
80.91 M USD
Jan 1, 2023
40.83 M USD
The Athersys Operating Expenses history
YEAROperating ExpensesYoY
40.83 MUSD-49.54%
80.91 MUSD-11.22%
91.15 MUSD+15.55%
78.88 MUSD+56.44%
50.42 MUSD+2.70%
49.10 MUSD+35.23%
36.31 MUSD+11.12%
32.67 MUSD+13.24%
28.85 MUSD-4.70%
30.28 MUSD
Access this data via the Eulerpool API

Athersys Stock analysis

What does Athersys do? Athersys Inc. is a biopharmaceutical company based in Cleveland, Ohio. It was founded in 1995 and focuses on the discovery, development, and commercialization of regenerative therapies and cell therapies. The idea for founding Athersys Inc. came from the vision that stem cell therapies could change the way we treat diseases. In the early stages of the company, the team focused on isolating and characterizing human stem cells. Over time, the research evolved and Athersys Inc. shifted its focus to developing drugs that promote tissue and organ regeneration. Athersys Inc.'s business model involves developing stem cell-based medications that are tested in clinical trials. The goal is to combat diseases such as stroke, heart attack, inflammatory diseases, and respiratory syndromes. Athersys Inc. utilizes a proprietary technology platform called MultiStem to isolate, expand, and differentiate stem cells. The company works closely with clinical partners in the pharmaceutical and biotech industry to conduct clinical trials and bring medications to market. Athersys has four divisions: Hematology, Neurology, Pulmonology, and Cardiology. In hematology, Athersys focuses on developing a therapy for cancer treatment. By administering MultiStem, a type of stem cell therapy, they hope to reduce the side effects of chemotherapy and kill cancer cells. In neurology, Athersys focuses on developing medications for the treatment of strokes and neurological disorders. The goal is to trigger regenerative processes in the brain and promote the growth of nerve cells and the regeneration of brain tissue. In pulmonology, Athersys focuses on developing therapies for the treatment of lung diseases such as ARDS and COPD. In cardiology, Athersys aims to improve the healing process after a heart attack by supporting the natural regeneration process of the heart muscle. Athersys' products are still in development and are in various stages of clinical trials. The most well-known product of Athersys is the MultiStem product. The company utilizes its proprietary technology platform to isolate and expand stem cells from human bone marrow and adipose tissue. MultiStem is intended to promote tissue regeneration and reduce inflammation. It has been tested in various preclinical and clinical trials and has shown promising results. Overall, Athersys Inc. is a company that focuses on regenerative therapies and cell therapies. By utilizing its proprietary technology platform MultiStem, Athersys hopes to develop stem cell-based therapies that can contribute to the cure of many different diseases. Although the company is still in the development and study phase, Athersys has already made impressive progress and remains an important player in the biopharmaceutical industry. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Total Operating Expenses of Athersys is 40.83 M USD in 2026.

Total Operating Expenses of Athersys changed from 80.91 M USD to 40.83 M USD, representing a -49.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Athersys since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Athersys historically and in real time.

Access this data via the Eulerpool API

Income Statement — Athersys

All Key Metrics — Athersys